Receive The Newest Study Notifications

Alkahest, Inc., a clinical stage biotechnology company focused on developing transformative therapies to treat age-related diseases, today announced the dosing of the first patient in AKST6021-211, a phase 2 clinical trial of its proprietary human plasma fraction,...

- ActoBio Therapeutics, Inc., a wholly owned subsidiary of Intrexon Corporation (NASDAQ: XON) and innovative clinical-stage biotechnology company focused on a new class of microbe-based therapeutic agents, announced that the U.S. Food and Drug Administration (FDA) has...

Trial will evaluate the effectiveness of perivascular sirolimus to improve AV Fistula outcomes in patients with kidney disease Vascular Therapies, a biotechnology company focused on improving vascular access outcomes in patients with kidney disease, today announced...

Henry Ford Cancer Institute first to put patient in GBM Agile Trial, which aims to identify most effective therapies for patients with glioblastoma August 15, 2019 — Henry Ford Cancer Institute is first-in-the-world to enroll a glioblastoma patient in the GBM AGILE...

dysfunction. This is a dose ranging, multicenter, randomized, double-blind, placebo-controlled, home use, parallel group clinical trial of MED2002, which is a topical gel developed by UK-based pharmaceutical company Futura Medical. The study's participants are males...

Join an industry expert in this free webinar to learn about trends in the clinical trial supply chain landscape and how sponsors can adapt and respond to change using new approaches to supply chain management. The clinical trial supply chain landscape is constantly...

 IQVIA™ (NYSE:IQV) announces its launch of the IQVIA Patient Portal, a global web-based solution built on a leading health cloud platform. This innovative tool enables increases in clinical trial patient recruitment, engagement and retention by ensuring transparency...

With over 2.40 billion monthly active users, Facebook stands as the largest social media platform in the world. It also boasts a user base that, collectively, comes from different regions, ranging from the United States to Canada to Asia. For patient recruitment...

Study met primary endpoint, verified HRS-1 reversal including three components: renal function improvement, avoidance of dialysis and short-term survival CONFIRM is the largest-ever prospective study (n=300) conducted in patients with HRS-1, an acute and rare disease...

VistaGen Therapeutics (VTGN), a clinical-stage biopharmaceutical company developing new generation medicines for central nervous system (CNS) diseases and disorders with high unmet need, announced today that the Company has achieved completion of target patient...

Bio-Thera Solutions, a clinical-stage pharmaceutical company, today announced that dosing has begun in a Phase I clinical study to compare the pharmacokinetics and safety of BAT2506, a proposed biosimilar of Simponi® (golimumab), to EU-sourced Simponi® in normal...

D&D Pharmatech, based in Gyenggi-Do, Korea and Germantown, Maryland, closed on a Series B financing round worth $137.1 million. The financing was led by U.S.-based Octave Life Sciences and Korean venture firm Smilegate Investment. Investors included InterVest,...

Emalex Biosciences, Inc., a biopharmaceutical company developing innovative therapies for patients with neurological and psychiatric conditions, announced today that the first patient was recently enrolled in the company’s international Phase 2b study to evaluate the...

Soliton, Inc., (Nasdaq: SOLY) ("Soliton" or the "Company"), a medical device company with a novel and proprietary platform technology licensed from The University of Texas on behalf of the MD Anderson Cancer Center ("MD Anderson"), today announced that the Company has...

Clinical development plan and Accelerated Approval regulatory path confirmed Phase 3 trial to initiate in the first quarter of 2020 and intended to support both major bleeding and surgery indications Conference call and webcast today at 8:30 a.m. EDT MALVERN, Pa. and...

Henry Ford Cancer Institute is first-in-the-world to enroll a patient in the GBM AGILE Trial (Adaptive Global Innovative Learning Environment) – a novel trial design and architecture made possible by an international collaboration of experts in the care of patients...

- Study results showed that StrataGraft-treated deep partial-thickness burns did not require surgical harvest of healthy skin by 28 days - - StrataGraft is currently being evaluated in an ongoing pivotal Phase 3 clinical trial - STAINES-UPON-THAMES, UK I August 13,...

AIVITA Biomedical, Inc., a biotech company specializing in innovative stem cell applications, announced today updated clinical data from its ongoing glioblastoma Phase 2 clinical trial, investigating AIVITA's platform immunotherapy targeting tumor-initiating cells....

ReNetX Bio, Inc., a leading biotechnology company committed to reversing disease and damage for patients suffering from central nervous system (CNS) disorders, has announced a successful first patient dosing in a Phase 1 clinical trial of its lead drug candidate,...

Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a biopharmaceutical company focused on the development of therapeutic drugs for the treatment of liver disease arising from non-alcoholic steatohepatitis (“NASH”) and chronic viral infection, today announced that it has...